Objective To construct the eukaryotic expression recombinant plasmid, pcIFN γ, as a genetic adjuvant and observe the immune responses elicited by pcDNA3 rhoptry protein 1 (pc ROP1) combined with pcIFN γ aga...Objective To construct the eukaryotic expression recombinant plasmid, pcIFN γ, as a genetic adjuvant and observe the immune responses elicited by pcDNA3 rhoptry protein 1 (pc ROP1) combined with pcIFN γ against Toxoplasma gondii (T gondii) infection in mice Methods A fragment of the IFN γ gene was directly inserted into the pcDNA3 plasmid and identified by two restriction endonucleases digestion pcIFN and pcROP1 DNA was injected into the left leg muscle of mice at a dosage of 100?μg, and a booster vaccination was given at the same dosage after two weeks Control groups were injected with pcDNA3 blank plasmid or normal saline At 30, 50 and 70 days after booster injection, kinetic tests were carried out: MTT assay for the proliferation response of T lymphocyte cells and the activity of NK cells, sandwich ABC ELISA for the determination of IFN γ, IL 2 and IL 10; a serum enzymetic aassay for nitric oxide (NO) in sera and ELISA for the titer of IgG antibody in sera Results The recombinant plasmid, pcIFN γ was constructed The proliferation response of spleen T lymph cells, NK cell killing activity, and serum levels of IFN γ, IL 2 and NO in mice injected with pcROP1 and pcIFN γ were higher than in those injected with pcROP1 alone There was no difference in IgG antibody levels between the two groups Conclusion The genetic adjuvant, pcIFN γ, could enhance the cellular immune response induced by DNA vaccine of pcROP1 in mice against Toxoplasma gondii infection展开更多
As an attractive alternative to plasmid DNA, messenger RNA （mRNA） has recently emerged as a promising class of nucleic acid therapeutics for biomedical applications. Advances in addressing the inherent shortcomings ...As an attractive alternative to plasmid DNA, messenger RNA （mRNA） has recently emerged as a promising class of nucleic acid therapeutics for biomedical applications. Advances in addressing the inherent shortcomings of mRNA and in the development of nanoparticle-based delivery systems have prompted the development and clinical translation of mRNA-based medicines. In this review, we discuss the chemical modification strategies of mRNA to improve its stability, minimize immune responses, and enhance translational efficacy. We also highlight recent progress in nanoparticle-based mRNA delivery. Considerable attention is given to the increasingly widespread applications of mRNA nanomedicine in the biomedical fields of vaccination, protein-replacement therapy, gene editing, and cellular reprogramming and engineering.展开更多
为研制一种能有效控制猪圆环病毒2型(porcine circovirus type 2,PCV2)的新型疫苗,本试验将PCV2的ORF2基因克隆至植物乳杆菌表达载体pSCPSP超强启动子SCP的下游,构建重组表达质粒pSCPSP-Cap,用电击转化法转化克隆至表达宿主菌植物乳杆菌...为研制一种能有效控制猪圆环病毒2型(porcine circovirus type 2,PCV2)的新型疫苗,本试验将PCV2的ORF2基因克隆至植物乳杆菌表达载体pSCPSP超强启动子SCP的下游,构建重组表达质粒pSCPSP-Cap,用电击转化法转化克隆至表达宿主菌植物乳杆菌,获得一株重组植物乳杆菌。以SDS-PAGE和Western blotting法检测24h上清液中表达的蛋白;将8周龄的SPF级BALB/c小鼠随机分组,每组8只,分别设置对照组、空载体组、灌胃组、饮水组、灭活疫苗组,试验14、28、42和56d后对小鼠采血,分离血清,利用PCV2ELISA抗体检测试剂盒检测小鼠血清中PCV2的抗体水平。SDS-PAGE、Western blotting结果显示,PCV2衣壳蛋白在植物乳杆菌中成功分泌表达,表达的蛋白分子质量为28ku,且具有良好的反应原性,重组植物乳杆菌免疫小鼠诱导机体产生PCV2特异性抗体显著高于其他组(P<0.05)。结果表明,PCV2的ORF2基因在植物乳杆菌中成功表达,且具有良好的生物活性,可为PCV2口服疫苗的开发研究提供理论参考。展开更多
Vaccination is critical for population protection from pathogenic infections.However,its efficiency is frequently compromised by a failure of antigen retention and presentation.Herein,we designed a dextran-binding pro...Vaccination is critical for population protection from pathogenic infections.However,its efficiency is frequently compromised by a failure of antigen retention and presentation.Herein,we designed a dextran-binding protein DexBP,which is composed of the carbohydrate-binding domains of Trichoderma reesei cellobiohydrolases Cel6A and Cel7A,together with the sequence of the fluorescent protein mCherry.DexBP was further prepared by engineered Escherichia coli cells and grafted to magnetic nanoparticles.The magnetic nanoparticles were integrated with a dextran/poly(vinyl alcohol)framework and a reactive oxygen species-responsive linker,obtaining magnetic polymeric microgels for carrying pathogen antigen.Similar to amoeba aggregation,the microgels self-assembled to form aggregates and further induced dendritic cell aggregation.This step-by-step assembly retained antigens at lymph nodes,promoted antigen presentation,stimulated humoral immunity,and protected the mice from lifethreatening systemic infections.This study developed a magnetic microgel-assembling platform for dynamically regulating immune response during protection of the body from dangerous infections.展开更多
目的探讨高迁移率族蛋白B1(HMGB1)分子与人乳头瘤病毒(HPV)16型E6E7重组腺病毒载体疫苗免疫效果的关系及机制。方法通过TC-1细胞移植诱导建立小鼠肿瘤模型,在接种HPV重组腺病毒载体疫苗的同时,给予注射HMGB1特异性拮抗剂HMGB1 A box,开...目的探讨高迁移率族蛋白B1(HMGB1)分子与人乳头瘤病毒(HPV)16型E6E7重组腺病毒载体疫苗免疫效果的关系及机制。方法通过TC-1细胞移植诱导建立小鼠肿瘤模型,在接种HPV重组腺病毒载体疫苗的同时,给予注射HMGB1特异性拮抗剂HMGB1 A box,开展肿瘤抑制试验、小鼠免疫状态观察、肿瘤相关信号检测等研究。结果 A box蛋白与疫苗联用,可显著降低模型小鼠HMGB1血清水平,抑制肿瘤组织中NF-?B的m RNA高表达,提高疫苗的抗肿瘤活性。同时,它还可减少IL-4、促进IFN-?产生,使体内免疫平衡由Th2向Th1偏移。和肿瘤模型对照组相比,在接种疫苗并注射A box蛋白后,由肿瘤引起的NF-?B、Bcl-2、c-IAP2、VEGF、MMP-9的表达提高、Bax表达降低均得到显著扭转。结论 HMGB1分子可以削弱HPV重组腺病毒载体疫苗的免疫效果,其机制可能是HMGB1在调节免疫平衡状态及控制肿瘤细胞的凋亡、浸润、转移等多层面均能参与并发挥重要作用。展开更多
文摘Objective To construct the eukaryotic expression recombinant plasmid, pcIFN γ, as a genetic adjuvant and observe the immune responses elicited by pcDNA3 rhoptry protein 1 (pc ROP1) combined with pcIFN γ against Toxoplasma gondii (T gondii) infection in mice Methods A fragment of the IFN γ gene was directly inserted into the pcDNA3 plasmid and identified by two restriction endonucleases digestion pcIFN and pcROP1 DNA was injected into the left leg muscle of mice at a dosage of 100?μg, and a booster vaccination was given at the same dosage after two weeks Control groups were injected with pcDNA3 blank plasmid or normal saline At 30, 50 and 70 days after booster injection, kinetic tests were carried out: MTT assay for the proliferation response of T lymphocyte cells and the activity of NK cells, sandwich ABC ELISA for the determination of IFN γ, IL 2 and IL 10; a serum enzymetic aassay for nitric oxide (NO) in sera and ELISA for the titer of IgG antibody in sera Results The recombinant plasmid, pcIFN γ was constructed The proliferation response of spleen T lymph cells, NK cell killing activity, and serum levels of IFN γ, IL 2 and NO in mice injected with pcROP1 and pcIFN γ were higher than in those injected with pcROP1 alone There was no difference in IgG antibody levels between the two groups Conclusion The genetic adjuvant, pcIFN γ, could enhance the cellular immune response induced by DNA vaccine of pcROP1 in mice against Toxoplasma gondii infection
文摘As an attractive alternative to plasmid DNA, messenger RNA （mRNA） has recently emerged as a promising class of nucleic acid therapeutics for biomedical applications. Advances in addressing the inherent shortcomings of mRNA and in the development of nanoparticle-based delivery systems have prompted the development and clinical translation of mRNA-based medicines. In this review, we discuss the chemical modification strategies of mRNA to improve its stability, minimize immune responses, and enhance translational efficacy. We also highlight recent progress in nanoparticle-based mRNA delivery. Considerable attention is given to the increasingly widespread applications of mRNA nanomedicine in the biomedical fields of vaccination, protein-replacement therapy, gene editing, and cellular reprogramming and engineering.
基金This work was supported by the National Natural Science Foundation of China(Nos.3217010793 and 31870139)Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project(No.TSBICIP-KJGG-006)+1 种基金the Natural Science Foundation of Tianjin(No.19JCZDJC33800)the Fundamental Research Funds for the Central Universities.
文摘Vaccination is critical for population protection from pathogenic infections.However,its efficiency is frequently compromised by a failure of antigen retention and presentation.Herein,we designed a dextran-binding protein DexBP,which is composed of the carbohydrate-binding domains of Trichoderma reesei cellobiohydrolases Cel6A and Cel7A,together with the sequence of the fluorescent protein mCherry.DexBP was further prepared by engineered Escherichia coli cells and grafted to magnetic nanoparticles.The magnetic nanoparticles were integrated with a dextran/poly(vinyl alcohol)framework and a reactive oxygen species-responsive linker,obtaining magnetic polymeric microgels for carrying pathogen antigen.Similar to amoeba aggregation,the microgels self-assembled to form aggregates and further induced dendritic cell aggregation.This step-by-step assembly retained antigens at lymph nodes,promoted antigen presentation,stimulated humoral immunity,and protected the mice from lifethreatening systemic infections.This study developed a magnetic microgel-assembling platform for dynamically regulating immune response during protection of the body from dangerous infections.
文摘目的探讨高迁移率族蛋白B1(HMGB1)分子与人乳头瘤病毒(HPV)16型E6E7重组腺病毒载体疫苗免疫效果的关系及机制。方法通过TC-1细胞移植诱导建立小鼠肿瘤模型,在接种HPV重组腺病毒载体疫苗的同时,给予注射HMGB1特异性拮抗剂HMGB1 A box,开展肿瘤抑制试验、小鼠免疫状态观察、肿瘤相关信号检测等研究。结果 A box蛋白与疫苗联用,可显著降低模型小鼠HMGB1血清水平,抑制肿瘤组织中NF-?B的m RNA高表达,提高疫苗的抗肿瘤活性。同时,它还可减少IL-4、促进IFN-?产生,使体内免疫平衡由Th2向Th1偏移。和肿瘤模型对照组相比,在接种疫苗并注射A box蛋白后,由肿瘤引起的NF-?B、Bcl-2、c-IAP2、VEGF、MMP-9的表达提高、Bax表达降低均得到显著扭转。结论 HMGB1分子可以削弱HPV重组腺病毒载体疫苗的免疫效果,其机制可能是HMGB1在调节免疫平衡状态及控制肿瘤细胞的凋亡、浸润、转移等多层面均能参与并发挥重要作用。
